Diabetes and elevated hemoglobin a1c levels are associated with brain hypometabolism but not amyloid accumulation

Journal of Nuclear Medicine

Volumn 55, Issue 5, 2014, Pages 759-764

  Roberts, Rosebud O ^a   Knopman, David S ^a   Cha, Ruth H ^a   Mielke, Michelle M ^a   Pankratz, V Shane ^a   Boeve, Bradley F ^a   Kantarci, Kejal ^a   Geda, Yonas E ^b   Jack Jr , Clifford R ^a   Petersen, Ronald C ^a   Lowe, Val J ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Amyloid accumulation; Cerebral glucose metabolism; Diabetes; Hemoglobin A1c

Indexed keywords

AMYLOID; APOLIPOPROTEIN E3; CARBON 11; FLUORODEOXYGLUCOSE F 18; HEMOGLOBIN A1C; PITTSBURGH COMPOUND B;

AGE; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; BIOACCUMULATION; BRAIN HYPOMETABOLISM; BRAIN METABOLISM; CONTROLLED STUDY; DISEASE ASSOCIATION; EDUCATIONAL STATUS; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; NON INSULIN DEPENDENT DIABETES MELLITUS; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRIORITY JOURNAL; VERY ELDERLY;

11C-PIB PET IMAGING; 18F-FDG PET IMAGING; AMYLOID ACCUMULATION; CEREBRAL GLUCOSE METABOLISM; DIABETES; HEMOGLOBIN A1C;

AGED; AGED, 80 AND OVER; ALLELES; ALZHEIMER DISEASE; AMYLOID; APOLIPOPROTEIN E4; BRAIN; CARBON RADIOISOTOPES; COGNITION; DIABETES MELLITUS, TYPE 2; FEMALE; FLUORODEOXYGLUCOSE F18; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; INSULIN; MALE; ODDS RATIO; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84901299033     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.132647     Document Type: Article

References (41)

1. Akomolafe A, Beiser A, Meigs JB, et al. Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. Arch Neurol. 2006;63: 1551-1555.
2. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol. 2004;61:661-666.
3. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC, Butler PC. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes. 2004;53:474-481.
4. MacKnight C, Rockwood K, Awalt E, McDowell I. Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord. 2002;14:77-83.
5. Luchsinger JA, Tang MX, Stern Y, Shea S, Mayeux R. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol. 2001;154:635-641.
6. Debette S, Seshadri S, Beiser A, et al. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology. 2011;77:461-468.
7. Arvanitakis Z, Schneider JA, Wilson RS, et al. Diabetes is related to cerebral infarction but not to AD pathology in older persons. Neurology. 2006;67:1960-1965.
8. Marchant NL, Reed BR, Sanossian N, et al. The aging brain and cognition: contribution of vascular injury and ab to mild cognitive dysfunction. JAMA Neurol. 2013;70:488-495.
9. Chui HC, Zarow C, Mack WJ, et al. Cognitive impact of subcortical vascular and Alzheimer's disease pathology. Ann Neurol. 2006;60:677-687.
10. Cherbuin N, Sachdev P, Anstey KJ. Higher normal fasting plasma glucose is associated with hippocampal atrophy: the PATH Study. Neurology. 2012;79:1019-1026.
11. Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes. 2002;51:1256-1262.
12. Alafuzoff I, Aho L, Helisalmi S, Mannermaa A, Soininen H. Beta-amyloid deposition in brains of subjects with diabetes. Neuropathol Appl Neurobiol. 2009;35:60-68.
13. Heitner J, Dickson D. Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects: a retrospective postmortem immunocytochemical and histofluorescent study. Neurology. 1997;49:1306-1311.
14. Duarte AI, Moreira PI, Oliveira CR. Insulin in central nervous system: more than just a peripheral hormone. J Aging Res. 2012;2012:384017.
15. Roberts RO, Geda YE, Knopman DS, et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology. 2008;30:58-69.
16. St. Sauver JL, Grossardt BR, Yawn BP, Melton LJ III, Rocca WA. Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester Epidemiology Project. Am J Epidemiol. 2011;173:1059-1068.
17. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412-2414.
18. Pfeffer RI, Kurosaki TT, Harrah CH Jr, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol. 1982;37:323-329.
19. Kokmen E, Smith GE, Petersen RC, Tangalos E, Ivnik RC. The short test of mental status. Correlations with standardized psychometric testing. Arch Neurol. 1991;48:725-728.
20. Ivnik RJ, Malec JF, Smith GE, et al. Mayo's older Americans normative studies: WAIS-R, WMS-R and AVLT norms for ages 56 through 97. Clin Neuropsychol. 1992;6:(suppl):1-30, 49-82, 83-104.
21. Petersen RC, Roberts RO, Knopman DS, et al. Prevalence of mild cognitive impairment is higher in men: the Mayo Clinic Study of Aging. Neurology. 2010;75:889-897.
22. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183-194.
23. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. 4th ed.Washington, DC: American Psychiatric Association; 1994.
24. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003;26:S5-S20.
25. Jack CR Jr, Bernstein MA, Fox NC, et al. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J Magn Reson Imaging. 2008;27:685-691.
26. Lowe VJ, Kemp BJ, Jack CR Jr, et al. Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med. 2009;50:878-886.
27. Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain. 2008;131:665-680.
28. Knopman DS, Jack CR Jr, Wiste HJ, et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology. 2012;78:1576-1582.
29. Landau SM, Harvey D, Madison CM, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging. 2011;32:1207-1218.
30. Jagust WJ, Landau SM, Shaw LM, et al. Relationships between biomarkers in aging and dementia. Neurology. 2009;73:1193-1199.
31. Landau SM, Harvey D, Madison CM, et al. Comparing predictors of conversion and decline in mild cognitive impairment. Neurology. 2010;75:230-238.
32. Jack CR, Knopman DS, Weigand SD, et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol. 2012;71:765-775.
33. Knopman DS, Jack CR Jr, Wiste HJ, et al. Brain injury biomarkers are not dependent on b-amyloid in normal elderly. Ann Neurol. 2012;73:472-480.
34. Jagust WJ, Landau SM. Apolipoprotein E, not fibrillar beta-amyloid, reduces cerebral glucose metabolism in normal aging. J Neurosci. 2012;32:18227-18233.
35. Roberts RO, Geda YE, Knopman DS, et al. The incidence of MCI differs by subtype and is higher in men: The Mayo Clinic Study of Aging. Neurology. 2012;78:342-351.
36. Baker LD, Cross DJ,Minoshima S, Belongia D,Watson GS, Craft S. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol. 2011;68:51-57.
37. Burns CM, Chen K, Kaszniak AW, et al. Higher serum glucose levels are associated with cerebral hypometabolism in Alzheimer regions. Neurology. 2013;80:1557-1564.
38. Petrovitch H, White LR, Izmirilian G, et al. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia Aging Study. Neurobiol Aging. 2000;21:57-62.
39. Qiu WQ, Folstein MF. Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Neurobiol Aging. 2006;27:190-198.
40. Hoyer S. The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update. J Neural Transm. 2002;109:341-360.
41. Thambisetty M, Metter EJ, Yang A, et al. Glucose intolerance, insulin resistance, and pathological features of Alzheimer disease in the Baltimore Longitudinal Study of Aging. JAMA Neurol. 2013;70:1167-1172.